ARTICLE | Finance
Launches stratified
Investors still trying to figure out bets on biotech product launches in 4Q11
October 3, 2011 7:00 AM UTC
The dramatic change in sales projections for Provenge sipuleucel-T from Dendreon Corp. on Aug. 2 was a watershed moment for biotech launch stories. Going into 4Q, some investors are still sorting out their bets on the commercialization stories.
Indeed, according to a price-weighted index compiled by BioCentury, the post-approval performance of 21 companies launching their first or second drug in 2010 or 2011 has declined 40% this year (see "Launch Performance"). ...